Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study

国家医疗保健体系中糖尿病发病年龄对1型糖尿病患者确诊15年后视网膜病变和微量白蛋白尿患病率的影响:一项横断面真实世界观察研究

阅读:1

Abstract

AIMS: This study investigates the impact of the era of diabetes onset on the prevalence of diabetic retinopathy and albuminuria 15 years post-diagnosis in people living with type 1 diabetes (T1D) within a national healthcare system offering structured multidisciplinary endocrinology care. MATERIALS AND METHODS: We analysed data of 2176 individuals diagnosed with T1D before age 30, comparing two cohorts based on diabetes onset period: group A (1985-1998) and group B (1998-2009). The prevalence of diabetic retinopathy and albuminuria was assessed using generalised estimating equations. RESULTS: Glycaemic control (haemoglobin A1C: 8.3% vs. 8.1%, p < 0.0001) and low density lipoprotein cholesterol (2.6 mmol/L vs. 2.5 mmol/L, p < 0.001) were poorer in group A, whereas obesity prevalence was higher in group B (12.8% vs. 17.4%, p < 0.01). Group A used more antihypertensive therapy (14.9% vs. 11.5%, p < 0.01), while group B used more lipid-lowering therapy (9.2% vs. 15.9%, p < 0.0001). The prevalence of diabetic retinopathy 15 years post-diagnosis significantly declined from 36.3% in 2001 to 21.1% in 2022 (p < 0.0001). This decrease was particularly pronounced in individuals with diabetes onset after 11 years of age. The prevalence of albuminuria, adjusted for age and sex, decreased from 14.9% in 2001 to 7.3% in 2022 (p < 0.05). CONCLUSIONS: Individuals diagnosed with T1D after 1998 had fewer microvascular complications 15 years post-diagnosis, especially less retinopathy in those with diabetes onset after age 11. This decline highlights the impact of improved care.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。